Abstract: A transport vehicle for use in a production facility is presented. The vehicle includes a support table for carrying material loads that can be lifted and rotated. The vehicle includes an autonomous mobile robot as a base transport unit to which lift and rotate functionalities are provided. The lift functionality is provided by lift control elements of a baseplate assembly fixated to the base transport unit. The rotate functionality is provided by support roller elements of a top plate assembly that is fixated to stability control elements of the baseplate assembly and interacts with the lift control elements. The support table rests on the support roller elements and is rotated via activation of one or more of the support roller elements. When assembled, centers of the top plate assembly and the support table align and coincide with a rotation axis of the support table.

Abstract: A first device is configured to establish a connection over a short-range communication link with a second device. The first device may transition to a sleep state, terminate (i) a paging operation and a page scanning operation associated with a paging protocol and (ii) an advertisement scanning operation associated with an advertisement protocol and perform an advertisement broadcast operation associated with the advertisement protocol, the advertisement broadcast operation generating an advertisement to be broadcast at a first interval, wherein the first interval is greater than a second interval for performing advertisement broadcast operations in an active state.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Abstract: Provided herein, inter alia, are methods and compositions for engineering T cells. The methods include contacting a T cell with a nucleic acid and one or more cyclic GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) pathway inhibitors. The methods provided herein are contemplated to increase cell viability, expansion and gene editing efficiency, thereby allowing an increase in the total number of engineered T cells.

Abstract: Provided herein, inter alia, are methods and compositions for engineering T cells. The methods include culturing a T cell with insulin during engineering of the T cell. The methods provided herein are contemplated to increase cell viability, expansion and gene editing efficiency, thereby allowing an increase in the total number of engineered T cells.

Abstract: An example mobile device location assertion verification method includes: obtaining, at an apparatus, an assertion of a first mobile device being at a first location at a first time; obtaining, at the apparatus, first indications of a radio frequency environment corresponding to the first mobile device, the first location, and the first time; obtaining, at the apparatus, second indications of a second radio frequency environment corresponding to a second mobile device, a second location, and a second time; correlating, at the apparatus, the first indications and the second indications; and performing an action at the apparatus in response to the correlating.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: The present disclosure relates to engineered T cells and methods of making and using the same, as well as reagents for making the engineered T cells.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Abstract: The present disclosure relates to engineered T cells and methods of making and using the same, as well as reagents for making the engineered T cells.

Abstract: A method includes, by a computing system, receiving a querying image depicting a sampling area, processing the querying image using a single cluster detection model to identify one or more regions of the querying image depicting a cluster in the sampling area, processing the one or more regions using a cluster verification deep-learning model to determine whether each depicted cluster is a cell cluster, and determining that exactly one of the identified one or more regions depicts a cluster that is a cell cluster. The method further includes processing the region depicting the cell cluster using a morphology deep-learning model to determine that there is only one cell in the cell cluster and to determine that die morphology of the cell is acceptable.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Abstract: A management service can receive an installation request for a client application from a first client device, where the installation request specifies a second client device on which the client application is to be installed. The management service can identify an operating system associated with the second client device. The management service can request installation of the client application on the second client device from an application catalog service associated with the operating system of the second client device.

Abstract: Disclosed are various approaches for workflow service back end integration. In some examples, a command is transmitted causing a client device to present a workflow action to perform. A user command to perform the workflow action is identified using the client device. Authentication data including user credentials and a navigation action for a visual user interface is identified. The user credentials are transmitted to the network service and an emulation of the navigation action is performed. A command that performs the workflow action is transmitted to the network service.

Abstract: There is disclosed a system, including apparatus, methods and computer programs, for running native software applications (apps) and HTML5 web-based apps on a computing device, particularly a mobile computing device, in a multitasking mode of operation. In one embodiment, touch screen displays having one or more browsers are adapted to run one or more HTML5 apps, and receive input from hand gestures. One or more software modules execute on the operating system and are responsive to a dragging gesture applied to an HTML5 app displayed in a full screen mode, to subdivide the screen display and display the HTML5 app in one of the subdivided areas and display icons used to launch a second HTML5 app in a different one of the subdivided areas. The second HTML5 app is run concurrently with the first HTML5 app in order to provide multi-tasking between the first and second apps.

Abstract: Disclosed are various approaches for polling federated services for notifications. A request for an access token for a federated service is sent to an authentication service. The access token for the federated service is received from the authentication service. A query is sent to the federated service for a notification, the query comprising the access token. The notification is received from the federated service.

Abstract: Disclosed are various approaches for workflow service back end integration. In some examples, a workflow service identifies a workflow action and a user account that is responsible for the workflow action. A command to present the workflow action for user authorization is transmitted to a client device associated with the user account. The workflow service transmits a command to perform the workflow action based on an identification of the user authorization.

Abstract: A first device is configured to establish a connection over a short-range communication link with a second device. The first device may transition to a sleep state, terminate (i) a paging operation and a page scanning operation associated with a paging protocol and (ii) an advertisement scanning operation associated with an advertisement protocol and perform an advertisement broadcast operation associated with the advertisement protocol, the advertisement broadcast operation generating an advertisement to be broadcast at a first interval, wherein the first interval is greater than a second interval for performing advertisement broadcast operations in an active state.

Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.